21 Aug 2023 --- US industry stakeholders call for cannabidiol (CBD) products to be regulated as a supplement instead of developing a new regulatory pathway as the US Food and Drug Administration (FDA) has decided. Stakeholders are responding to a Congressional Request for Information (RFI) on creating a “regulatory pathway for non-intoxicating hemp-derived CBD products that prioritizes consumer safety and provides certainty to the US markets.” The RFI for stakeholders included questions on market dynamics, regulatory pathways and scope, federal-state regulatory and enforcement interactions, public safety and risk, consumer protections and quality controls, plus inquiries related to product form, packaging, accessibility and labeling.
